[1]
|
Rodríguez-Camacho, A., Flores-Vázquez, J.G., Moscardini-Martelli, J., Torres-Ríos, J.A., Olmos-Guzmán, A., Ortiz-Arce, C.S., et al. (2022) Glioblastoma Treatment: State-of-the-Art and Future Perspectives. International Journal of Molecular Sciences, 23, Article No. 7207. https://doi.org/10.3390/ijms23137207
|
[2]
|
Thakur, A., Faujdar, C., Sharma, R., Sharma, S., Malik, B., Nepali, K. and Liou, J.P. (2022) Glioblastoma: Current Status, Emerging Targets, and Recent Advances. Journal of Medicinal Chemistry, 65, 8596-8685. https://doi.org/10.1021/acs.jmedchem.1c01946
|
[3]
|
Khaddour, K., Johanns, T.M. and Ansstas, G. (2020) The Landscape of Novel Therapeutics and Challenges in Glioblastoma Multiforme: Contemporary State and Future Directions. Pharmaceuticals (Basel), 13, Article No. 389. https://doi.org/10.3390/ph13110389
|
[4]
|
Huang, B., Zhang, H., Gu, L., Ye, B., Jian, Z., Stary, C. and Xiong, X. (2017) Advances in Immunotherapy for Glioblastoma Multiforme. Journal of Immunology Research, 2017, Article ID: 3597613. https://doi.org/10.1155/2017/3597613
|
[5]
|
Ahir, B.K., Engelhard, H.H. and Lakka, S.S. (2020) Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma. Molecular Neurobiology, 57, 2461-2478. https://doi.org/10.1007/s12035-020-01892-8
|
[6]
|
Ostrom, Q.T., Cioffi, G., Waite, K., Kruchko, C. and Barnholtz-Sloan, J.S. (2021) CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. Neuro-Oncology, 23, iii1-iii105. https://doi.org/10.1093/neuonc/noab200
|
[7]
|
Ostrom, Q.T., Patil, N., Cioffi, G., Waite, K., Kruchko, C. and Barnholtz-Sloan, J.S. (2020) CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. Neuro-Oncology, 22, iv1-iv96. https://doi.org/10.1093/neuonc/noaa200
|
[8]
|
Kroemer, G., Galluzzi, L., Kepp, O. and Zitvogel, L. (2013) Immunogenic Cell Death in Cancer Therapy. Annual Review of Immunology, 31, 51-72. https://doi.org/10.1146/annurev-immunol-032712-100008
|
[9]
|
Casares, N., Pequignot, M.O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., et al. (2005) Caspase-Dependent Immunogenicity of Doxorubicin-Induced Tumor Cell Death. Journal of Experimental Medicine, 202, 1691-1701. https://doi.org/10.1084/jem.20050915
|
[10]
|
Kroemer, G., Galassi, C., Zitvogel, L. and Galluzzi, L. (2022) Immunogenic Cell Stress and Death. Nature Immunology, 23, 487-500. https://doi.org/10.1038/s41590-022-01132-2
|
[11]
|
Garg, A.D., De Ruysscher, D. and Agostinis, P. (2016) Immunological Metagene Signatures Derived from Immunogenic Cancer Cell Death Associate with Improved Survival of Patients with Lung, Breast or Ovarian Malignancies: A Large-Scale Meta-Analysis. Oncoimmunology, 5, e1069938. https://doi.org/10.1080/2162402X.2015.1069938
|
[12]
|
Wilkerson, M.D. and Hayes, D.N. (2010) ConsensusClusterPlus: A Class Discovery Tool with Confidence Assessments and Item Tracking. Bioinformatics, 26, 1572-1573. https://doi.org/10.1093/bioinformatics/btq170
|
[13]
|
Mayakonda, A., Lin, D.-C., Assenov, Y., Plass, C. and Koeffler, H.P. (2018) Maftools: Efficient and Comprehensive Analysis of Somatic Variants in Cancer. Genome Research, 28, 1747-1756. https://doi.org/10.1101/gr.239244.118
|
[14]
|
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Trevino, V., et al. (2013) Inferring Tumour Purity and Stromal and Immune Cell Admixture from Expression Data. Nature Communications, 4, Article No. 2612. https://doi.org/10.1038/ncomms3612
|
[15]
|
Wu, J., Li, L., Zhang, H., Zhao, Y., Zhang, H., Wu, S. and Xu, B. (2021) A Risk Model Developed Based on Tumor Microenvironment Predicts Overall Survival and Associates with Tumor Immunity of Patients with Lung Adenocarcinoma. Oncogene, 40, 4413-4424. https://doi.org/10.1038/s41388-021-01853-y
|
[16]
|
Tsvetkov, P., Coy, S., Petrova, B., Dreishpoon, M., Verma, A., Abdusamad, M., et al. (2022) Copper Induces Cell Death by Targeting Lipoylated TCA Cycle Proteins. Science, 375, 1254-1261. https://doi.org/10.1126/science.abf0529
|
[17]
|
Fan, M.-D., Zhao, X.-Y., Qi, J.-N., Jiang, Y., Liu, B.-Y., Dun, Z.-P., Zhang, R., Wang, C.-W. and Pang, Q. (2020) TRIM31 Enhances Chemoresistance in Glioblastoma through Activation of the PI3K/Akt Signaling Pathway. Experimental and Therapeutic Medicine, 20, 802-809. https://doi.org/10.3892/etm.2020.8782
|
[18]
|
Geng, S., et al. (2021) LncRNA PITPNA-AS1 Stimulates Cell Proliferation and Suppresses Cell Apoptosis in Glioblastoma via Targeting miR-223-3p/EGFR Axis and Activating PI3K/AKT Signaling Pathway. Cell Cycle (Georgetown, Tex), 20, 1988-1998. https://doi.org/10.1080/15384101.2021.1958503
|
[19]
|
Wu, D.-M., Hong, X.-W., Wen, X., Han, X.-R., Wang, S., Wang, Y.-J., et al. (2019) MCL1 Gene Silencing Promotes Senescence and Apoptosis of Glioma Cells via Inhibition of the PI3K/Akt Signaling Pathway. IUBMB Life, 71, 81-92. https://doi.org/10.1002/iub.1944
|
[20]
|
Wang, M., Zhang, C., Zheng, Q., Ma, Z., Qi, M., Di, G., et al. (2022) RhoJ Facilitates Angiogenesis in Glioblastoma via JNK/VEGFR2 Mediated Activation of PAK and ERK Signaling Pathways. International Journal of Biological Sciences, 18, 942-955. https://doi.org/10.7150/ijbs.65653
|
[21]
|
Bhat, K.P.L., Balasubramaniyan, V., Vaillant, B., Ezhilarasan, R., Hummelink, K., Hollingsworth, F., et al. (2013) Mesenchymal Differentiation Mediated by NF-κB Promotes Radiation Resistance in Glioblastoma. Cancer Cell, 24, 331-346. https://doi.org/10.1016/j.ccr.2013.08.001
|
[22]
|
Soukhtanloo, M., Mohtashami, E., Maghrouni, A., Mollazadeh, H., Mousavi, S.H., Roshan, M.K., et al. (2020) Natural Products as Promising Targets in Glioblastoma Multiforme: A Focus on NF-κB Signaling Pathway. Pharmacological Reports, 72, 285-295. https://doi.org/10.1007/s43440-020-00081-7
|
[23]
|
Wang, H., et al. (2015) NF-κB Induces miR-148a to Sustain TGF-β/Smad Signaling Activation in Glioblastoma. Molecular Cancer, 14, Article No. 2. https://doi.org/10.1186/1476-4598-14-2
|
[24]
|
Ou, A., Ott, M., Fang, D. and Heimberger, A.B. (2021) The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma. Cancers (Basel), 13, Article No. 437. https://doi.org/10.3390/cancers13030437
|
[25]
|
Xia, Q., Ali, S., Liu, L., Li, Y., Liu, X., Zhang, L. and Dong, L. (2020) Role of Ubiquitination in PTEN Cellular Homeostasis and Its Implications in GB Drug Resistance. Frontiers in Oncology, 10, Article No. 1569. https://doi.org/10.3389/fonc.2020.01569
|
[26]
|
Guo, X.-Y., Zhang, G.-H., Wang, Z.-N., Duan, H., Xie, T., et al. (2021) A Novel Foxp3-Related Immune Prognostic Signature for Glioblastoma Multiforme Based on Immunogenomic Profiling. Aging (Albany NY), 13, 3501-3517. https://doi.org/10.18632/aging.202282
|
[27]
|
Liang, L., Yan, B., Liu, Y., Jiang, S., He, H., Huang, J., Liu, W. and Xie, L. (2022) FOXP3 Contributes to TMZ Resistance, Prognosis, and Immune Infiltration in GBM from a Novel Pyroptosis-Associated Risk Signature. Disease Markers, 2022, Article ID: 4534080. https://doi.org/10.1155/2022/4534080
|
[28]
|
Xue, H., Yuan, G., Guo, X., Liu, Q., Zhang, J., Gao, X., et al. (2016) A Novel Tumor-Promoting Mechanism of IL6 and the Therapeutic Efficacy of Tocilizumab: Hypoxia-Induced IL6 Is a Potent Autophagy Initiator in Glioblastoma via the p-STAT3-MIR155-3p-CREBRF Pathway. Autophagy, 12, 1129-1152. https://doi.org/10.1080/15548627.2016.1178446
|
[29]
|
Wang, Q., He, Z., Huang, M., Liu, T., Wang, Y., Xu, H., et al. (2018) Vascular Niche IL-6 Induces Alternative Macrophage Activation in Glioblastoma through HIF-2α. Nature Communications, 9, Article No. 559. https://doi.org/10.1038/s41467-018-03050-0
|
[30]
|
Nakamura, T., Tateishi, K., Niwa, T., Matsushita, Y., Tamura, K., Kinoshita, M., et al. (2016) Recurrent Mutations of CD79B and MYD88 Are the Hallmark of Primary Central Nervous System Lymphomas. Neuropathology and Applied Neurobiology, 42, 279-290. https://doi.org/10.1111/nan.12259
|
[31]
|
Chiavari, M., Ciotti, G.M.P., Canonico, F., Altieri, F., Lacal, P.M., Graziani, G., Navarra, P. and Lisi, L. (2020) PDIA3 Expression in Glioblastoma Modulates Macrophage/Microglia Pro-Tumor Activation. International Journal of Molecular Sciences, 21, E8214. https://doi.org/10.3390/ijms21218214
|
[32]
|
Li, T., Xu, J. and Liu, Y. (2021) A Novel Circular RNA CircRFX3 Serves as a Sponge for MicroRNA-587 in Promoting Glioblastoma Progression via Regulating PDIA3. Frontiers in Cell and Developmental Biology, 9, Article ID: 757260. https://doi.org/10.3389/fcell.2021.757260
|
[33]
|
Sauvageot, C.M.-E., Weatherbee, J.L., Kesari, S., et al. (2009) Efficacy of the HSP90 Inhibitor 17-AAG in Human Glioma Cell Lines and Tumorigenic Glioma Stem Cells. Neuro-Oncology, 11, 109-121. https://doi.org/10.1215/15228517-2008-060
|
[34]
|
Zhang, S., Peng, X., Li, X., et al. (2021) BKM120 Sensitizes Glioblastoma to the PARP Inhibitor Rucaparib by Suppressing Homologous Recombination Repair. Cell Death & Disease, 12, Article No. 546. https://doi.org/10.1038/s41419-021-03805-6
|
[35]
|
Su, Z., Han, S., Jin, Q., et al. (2021) Ciclopirox and Bortezomib Synergistically Inhibits Glioblastoma Multiforme Growth via Simultaneously Enhancing JNK/p38 MAPK and NF-κB Signaling. Cell Death & Disease, 12, Article No. 251. https://doi.org/10.1038/s41419-021-03535-9
|
[36]
|
Alhalabi, O.T., Fletcher, M.N.C., Hielscher, T., et al. (2022) A Novel Patient Stratification Strategy to Enhance the Therapeutic Efficacy of Dasatinib in Glioblastoma. Neuro-Oncology, 24, 39-51. https://doi.org/10.1093/neuonc/noab158
|
[37]
|
Yu, A., Faiq, N., Green, S., et al. (2017) Report of Safety of Pulse Dosing of Lapatinib with Temozolomide and Radiation Therapy for Newly-Diagnosed Glioblastoma in a Pilot Phase II Study. Journal of Neuro-Oncology, 134, 357-362. https://doi.org/10.1007/s11060-017-2533-6
|
[38]
|
Graff, J.R., McNulty, A.M., Hanna, K.R., et al. (2005) The Protein Kinase Cbeta-Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts. Cancer Research, 65, 7462-7469. https://doi.org/10.1158/0008-5472.CAN-05-0071
|
[39]
|
Li, G., Yang, T., Chen, Y., et al. (2021) USP5 Sustains the Proliferation of Glioblastoma through Stabilization of CyclinD1. Frontiers in Pharmacology, 12, Article ID: 720307. https://doi.org/10.3389/fphar.2021.720307
|
[40]
|
Yang, K., Shi, Y., Luo, M., et al. (2022) Identification of a Unique Tumor Cell Subset Employing Myeloid Transcriptional Circuits to Create an Immunomodulatory Microenvironment in Glioblastoma. Oncoimmunology, 11, Article ID: 2030020. https://doi.org/10.1080/2162402X.2022.2030020
|
[41]
|
Yang, J., Zhang, Q., Liu, Y., et al. (2020) Nanoparticle-Based Co-Delivery of siRNA and Paclitaxel for Dual-Targeting of Glioblastoma. Nanomedicine (London), 15, 1391-1409. https://doi.org/10.2217/nnm-2020-0066
|
[42]
|
Haraldsdottir, S., Janku, F., Poi, M., et al. (2018) Phase I Trial of Dabrafenib and Pazopanib in BRAF Mutated Advanced Malignancies. JCO Precision Oncology, 2, 1-19. https://doi.org/10.1200/PO.17.00247
|
[43]
|
Michaud, K., et al. (2010) Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts. Cancer Research, 70, 3228-3238. https://doi.org/10.1158/0008-5472.CAN-09-4559
|
[44]
|
Le Rhun, E., Preusser, M., Roth, P., et al. (2019) Molecular Targeted Therapy of Glioblastoma. Cancer Treatment Reviews, 80, Article ID: 101896. https://doi.org/10.1016/j.ctrv.2019.101896
|
[45]
|
Delen, E., Doganlar, O., Doganlar, Z.B. and Delen, O. (2020) Inhibition of the Invasion of Human Glioblastoma U87 Cell Line by Ruxolitinib: A Molecular Player of miR-17 and miR-20a Regulating JAK/STAT Pathway. Turkish Neurosurgery, 30, 182-189. https://doi.org/10.5137/1019-5149.JTN.26122-19.1
|
[46]
|
Kaley, T.J., Panageas, K.S., Pentsova, E.I., et al. (2020) Phase I Clinical Trial of Temsirolimus and Perifosine for Recurrent Glioblastoma. Annals of Clinical and Translational Neurology, 7, 429-436. https://doi.org/10.1002/acn3.51009
|
[47]
|
Yang, X., Yang, J.-A., Liu, B.-H., Liao, J.-M., Yuan, F.-E., Tan, Y.-Q. and Chen, Q.-X. (2017) TGX-221 Inhibits Proliferation and Induces Apoptosis in Human Glioblastoma Cells. Oncology Reports, 38, 2836-2842. https://doi.org/10.3892/or.2017.5991
|
[48]
|
Monticone, M., Biollo, E., Fabiano, A., et al. (2009) z-Leucinyl-leucinyl-norleucinal Induces Apoptosis of Human Glioblastoma Tumor-Initiating Cells by Proteasome Inhibition and Mitotic Arrest Response. Molecular Cancer Research, 7, 1822-1834. https://doi.org/10.1158/1541-7786.MCR-09-0225
|
[49]
|
Fuentes-Baile, M., Ventero, M.P., Encinar, J.A., et al. (2020) Differential Effects of IGF-1R Small Molecule Tyrosine Kinase Inhibitors BMS-754807 and OSI-906 on Human Cancer Cell Lines. Cancers (Basel), 12, E3717. https://doi.org/10.3390/cancers12123717
|
[50]
|
Feng, J., Yan, P.-F., Zhao, H.-Y., Zhang, F.-C., Zhao, W.-H. and Feng, M. (2016) Inhibitor of Nicotinamide Phosphoribosyltransferase Sensitizes Glioblastoma Cells to Temozolomide via Activating ROS/JNK Signaling Pathway. BioMed Research International, 2016, Article ID: 1450843. https://doi.org/10.1155/2016/1450843
|
[51]
|
He, Y., Meng, H., Xu, H., et al. (2018) Regulation of Integrated Stress Response Sensitizes U87MG Glioblastoma Cells to Temozolomide through the Mitochondrial Apoptosis Pathway. The Anatomical Record (Hoboken), 301, 1390-1397. https://doi.org/10.1002/ar.23839
|